LAG3 and cancer: These data suggest in addition to intact Fc function, GB265/GB266/GB266T-induced tumor cell-T cell bridging through PD-L1 on cancer cells and TIGIT/LAG-3 on T cells is a critical attribute for these antibodies to elicit efficient anti-cancer T cell response.